Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00128271 · ClinicalTrials.gov registry record · Phase 1

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

A Phase 1 study of Hepatitis C, sponsored by Peregrine Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT00128271 is a Phase 1 study of Hepatitis C that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 32 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00128271, a Phase 1 study of Hepatitis C, has completed, sponsored by Peregrine Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis C virus in individuals with chronic infection.

Conditions Studied

Hepatitis C

Interventions

  • DRUG Bavituximab

Study Locations (1)

Florida

  • Bach & Godofsky, MD, PA - Bradenton

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2005-08
Phase Phase 1

Sponsor

Peregrine Pharmaceuticals

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00128271

The ClinicalTrials.gov registry entry for NCT00128271 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Bavituximab is the first listed.

NCT00128271 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT00128271 about?

NCT00128271 is a clinical study titled "Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection". The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis C virus in individuals with chronic infection.

What is the current status of trial NCT00128271?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2005-08.

What conditions does trial NCT00128271 study?

This clinical trial studies the following conditions: Hepatitis C.

What interventions are being tested in trial NCT00128271?

The interventions under investigation include: Bavituximab (DRUG).

Who is sponsoring clinical trial NCT00128271?

This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00128271 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.